Carmot Therapeutics is a clinical-stage biotechnology company focused on the discovery of disease-modifying therapies in metabolic disease and cancer. It applies a proprietary drug discovery platform, Chemotype Evolution, to identify covalent inhibitors, small molecule ligands, and peptide-fragment hybrids.